A Randomized Controlled Trial of R-Form Verapamil Added to Ongoing Metformin Therapy in Patients with Type 2 Diabetes.

Chih-Yuan WangKuo-Chin HuangChia-Wen LuChih-Hsun ChuChien-Ning HuangHarn-Shen ChenI-Te LeeJung-Fu ChenChing-Chu ChenChung-Sen ChenChang-Hsun HsiehKai-Jen TienHung-Yu ChienYu-Yao HuangJui-Pao HsuGuang-Tzuu ShaneAi-Ching ChangYen-Chieh Wu Wayne Huey Herng Sheu

Published in: The Journal of clinical endocrinology and metabolism (2022)

Addition of R-Vera twice daily to ongoing metformin therapy significantly improved glycemic control in T2DM patients. The favorable efficacy and safety profile of R-Vera 300 mg/day can be considered as the appropriate dose for clinical practice.

Keyphrases

glycemic control
type diabetes
clinical practice
end stage renal disease
newly diagnosed
ejection fraction
blood glucose
prognostic factors
peritoneal dialysis
physical activity
weight loss
stem cells
insulin resistance
adipose tissue
metabolic syndrome
bone marrow
skeletal muscle
replacement therapy